Efficacy News and Research

RSS

New type of COVID vaccine potentially easier to produce and does not need refrigeration

Currently available COVID vaccines require cold storage and sophisticated manufacturing capacity, which makes it difficult to produce and distribute them widely, especially in less developed countries.

6 Nov 2021

Study opens a window for new therapeutic approaches to ovarian cancer

A Ludwig Cancer Research study has uncovered a cellular interaction that is essential to the ability of the immune system's cytotoxic T lymphocytes to destroy ovarian tumors and shown that its engagement could help determine the efficacy of checkpoint blockade immunotherapy in a variety of cancers.

6 Nov 2021

MHRA approves first oral antiviral for the treatment of COVID-19

The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency announced today.

4 Nov 2021

Study finds benefits of COVID vaccination in pregnancy outweighs risks

A new preprint explores the efficacy of vaccination against infection with SARS-CoV-2 in pregnancy.

4 Nov 2021

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

A new preprint describes the protective efficacy of memory T-cells developed in response to the viral antigen, which could offer long-term immunity.

4 Nov 2021

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

4 Nov 2021

Clear communication needed with college students regarding COVID-19 vaccine procedures and cost

A new study explores the acceptability and usage of COVID-19 vaccines among the student community.

4 Nov 2021

Novel model-based framework evaluates immune mechanism of COVID-19 vaccine response

A model framework for characterizing viral dynamics and vaccine efficacy in non-human primates is described and applied to the identification of correlates of protection in three independent vaccine studies.

4 Nov 2021

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

A comprehensive characterization of the immune responses between SARS-CoV-2 infected individuals with wildtype (WT) and Δ382 SARS-CoV-2.

3 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medications or switching to a biologic drug.

2 Nov 2021

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

2 Nov 2021

Virtual exercise program can be safe for people with osteoarthritis, research finds

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that a virtual exercise program can be safe for people with musculoskeletal conditions, improved their health outcomes, and helped them feel more socially connected, an important benefit during the pandemic when many people have chosen to avoid in-person exercise classes.

2 Nov 2021

Study: Ultra-low rituximab dose maintains low disease activity for most RA patients

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to switch to other biologic drugs or glucocorticoids to control their disease.

2 Nov 2021

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines.

2 Nov 2021

The pros and cons of a COVID-19 vaccine booster

The authors provide an overview of current literature available to assess the need for COVID-19 vaccine booster doses and their potential target population.

2 Nov 2021

Mitigating SARS-CoV-2 infection risks among essential food workers

Researchers employ a stochastic quantitative microbial risk assessment model to assess risk reduction measures for controlling SARS-CoV-2 transmission.

2 Nov 2021

End-stage renal disease negatively impacts COVID-19 vaccine response

Researchers perform a systematic review of people with end-stage kidney disease receiving SARS-CoV-2 vaccines to assess their immunogenicity rates.

2 Nov 2021

Zinc supplement may help prevent symptoms of respiratory tract infections, analysis finds

A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence, published in the open access journal BMJ Open.

2 Nov 2021

Efficacy News and Research

New type of COVID vaccine potentially easier to produce and does not need refrigeration

Study opens a window for new therapeutic approaches to ovarian cancer

MHRA approves first oral antiviral for the treatment of COVID-19

Study finds benefits of COVID vaccination in pregnancy outweighs risks

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

Clear communication needed with college students regarding COVID-19 vaccine procedures and cost

Novel model-based framework evaluates immune mechanism of COVID-19 vaccine response

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

Virtual exercise program can be safe for people with osteoarthritis, research finds

Study: Ultra-low rituximab dose maintains low disease activity for most RA patients

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

The pros and cons of a COVID-19 vaccine booster

Mitigating SARS-CoV-2 infection risks among essential food workers

End-stage renal disease negatively impacts COVID-19 vaccine response

Zinc supplement may help prevent symptoms of respiratory tract infections, analysis finds

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News